AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02271464 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maintenance:BEVACIZUMAB+CAPECITABINE+CYCLOPHOSPHAMIDE
Description: Patients will be randomly assigned to receive induction chemotherapy with the G.O.N.O. FOLFOXIRI regimen plus bevacizumab:~* BEVACIZUMAB 5 mg/kg over 30 minutes, day 1~* IRINOTECAN 165 mg/sqm IV over 1-h, day 1~* OXALIPLATIN 85 mg/sqm IV over 2-h, day 1~* L-LEUCOVORIN 200 mg/sqm IV over 2-h, day 1~* 5-FLUOROURACIL 3200 mg/sqm IV 48-h continuous infusion, starting on day 1~with cycles repeated every 2 weeks for 4 months (8 cycles), followed after 2 weeks by (if no progression occurs):~* BEVACIZUMAB 7.5 mg/kg over 30 minutes, day 1 (every three weeks),~* CAPECITABINE 500 mg/tid orally, continuously,~* CYCLOPHOSPHAMIDE 50 mg/day orally, continuously.
Study NCT00231777 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: MK0517
Description: a single administration of 40 mg MK0517 by IV immediately prior to surgery
Study NCT00231777 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: ondansetron
Description: a single administration of 4 mg ondansetron by IV immediately prior to surgery
Study NCT03658005 — intervention group
Intervention type: OTHER
Intervention: Blood sample
Description: 3 blood samples, for a maximum of 60mL, will be taken at 0-3h, 3-6h and >6h, between two doses of ticagrelor (taken at 0 and 12 hours).
Study NCT03367858 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI)
Description: Motivational interviewing introduced a conversation about alcohol use, and the personally-experienced consequences of problem drinking. The MI sessions explored youths' stories around their substance use, the factors in youths' lives that support problem drinking (e.g., what they like about drinking), and the consequences of their recent or previous problem drinking (e.g., getting in trouble). Youth were provided personalized feedback about how their problem drinking compared to age-matched norms in the U.S. The ultimate goal of the MI sessions was to engage youth in a thoughtful conversation about their problem drinking with an eye to bolstering and supporting youths' own inherent drive for behavior change.
Study NCT03367858 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief Adolescent Mindfulness (BAM)
Description: Brief Adolescent Mindfulness introduced a conversation about what mindfulness is, and ways that it might be personally-relevant to adolescents' current experiences. This manualized treatment introduced concepts of eastern thought in a manner articulated to adolescents. Treatment included a discussion of factors in the youth's life that could be positively impacted by using or engaging mindful approaches (e.g., current experiences of stress) and a link to how mindful approaches might be applicable or relevant to the adolescent's problem drinking. The ultimate goal was to engage youth in a thoughtful conversation about BAM and how eastern thought and mindful approaches could unburden some aspects of their current lived experiences.
Study NCT00363844 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin phosphate
Description: 50 mg QD or 100 mg QD for 12 months
Study NCT02308956 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrated mental health in primary care
Description: A task-shared model of collaborative mental health care integrated into the primary care setting.
Study NCT02308956 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychiatric nurse-led specialist care
Description: A centralised, psychiatric nurse-led, hospital out-patient service with outreach from project outreach workers
Study NCT03935321 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: 6 intrathecal bolus injections, each of 45mg
Study NCT00841555 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide
Description: Chemotherapy will be given for 5 weeks; it will start 1 week before Radiotherapy, will continue for the 3 weeks of Radiotherapy, and will continue for 1 week post-Radiotherapy.~Dose Level 1: 50 mg/m2 x first 4 weeks/75 mg/m2 x last 1 weeks of treatment Dose Level 2: 65 mg/m2 x first 4 weeks/75 mg/m2 x last 1 weeks of treatment Dose Level 3: 75 mg/m2 over the entire 5 weeks of treatment
Study NCT00118183 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Given IV
Study NCT00841555 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated radiation therapy
Description: Patients will undergo HIMRT
Study NCT00841555 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-modulated radiation therapy
Description: Patients undergo HIMRT
Study NCT00118183 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: Given IV
Study NCT03237546 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Anesthetic regimen including SB
Description: Group receiving general anesthesia with the serratus block
Study NCT00118183 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Given IV
Study NCT03237546 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Anesthetic regimen including SB or no block
Description: Group receiving general anesthesia alone
Study NCT02187627 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [11C]RO6924963
Description: Radiolabeled low molecular weight compound, administered as single intravenous injection. The mass dose of \[11C\]RO6924963 injected will be \</=10 micrograms (mcg), injection volume \</=20 milliliters (mL). Target injected activity for \[11C\]RO6924963 will be 370-740 megabecquerel (MBq) \[10-20 millicurie (mCi)\].
Study NCT02187627 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [11C]RO6931643
Description: Radiolabeled low molecular weight compound, administered as single intravenous injection. The mass dose of \[11C\]RO6931643 injected will be \</=10 mcg, injection volume \</=20 mL. Target injected activity for \[11C\]RO6931643 will be 370-740 MBq (10-20 mCi).
Study NCT02187627 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]RO6958948
Description: Radiolabeled low molecular weight compound, administered as single intravenous injection. The mass dose of \[18F\]RO6958948 injected will be \</=10 mcg, injection volume \</=20 mL. Target injected activity for \[18F\]RO6958948 will be 185-370 MBq (5-10 mCi). The final activity of \[18F\] RO6958948 will be adjusted up to 10 mCi per scan to allow sufficient counts by end of 200 minutes post radiotracer injection.
Study NCT04127708 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: acupuncture
Description: acupuncture group and control group
Study NCT04127708 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: acupuncture
Description: acupuncture group and control group
Study NCT04768374 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality with Kinect
Description: In the study it was conducted a 12 week-intensive VR intervention (twice a week, 45 minutes each) and compared the results in the 12th week to investigate the effects of rehabilitation and follow-up assessments were made in the 16th and 24th weeks. From the beginning of the VR intervention, each game was played in equal durations by each participant. However, the difficulty of the games varied depending on the child's performance.~Microsoft Kinect Games-Carnival Games was used as VR intervention. In meeting held with the authors to determine which games would be used in the VR program, 5 games were chosen and the remaining games were removed from the program because of their similar contents.
Study NCT04768374 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Occupational Therapy (COT)
Description: The COT based on neurodevelopmental treatment was carried out by the same occupational therapist. The treatment goals aimed at increasing the use of participant's extremities and improving the independence in ADL. The activities in the treatment were chosen in view of children's motor skills and daily living activities such as getting dressed, solving puzzles, and writing etc.~Both groups received COT while the control group received COT only for 12 weeks.
Study NCT04768374 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional Occupational Therapy (COT)
Description: The COT based on neurodevelopmental treatment was carried out by the same occupational therapist. The treatment goals aimed at increasing the use of participant's extremities and improving the independence in ADL. The activities in the treatment were chosen in view of children's motor skills and daily living activities such as getting dressed, solving puzzles, and writing etc.~Both groups received COT while the control group received COT only for 12 weeks.
Study NCT01222026 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Strontium Ranelate + Ca/Vitamin-D
Description: 2g Strontium Ranelate once daily 1000mg Calcium 800 IE Vitamin D
Study NCT01222026 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 1000mg Calcium 800 IE Vitamin-D
Study NCT01191268 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Glargine
Study NCT01191268 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2189265
Study NCT01191268 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Lispro
Study NCT01191268 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Lispro
Study NCT01660581 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: intramyocardial injection (electromechanical mapping based)
Description: Patient will undergo 3D electric and mechanical intracardiac mapping; based on maps generated intramyocardial administration of autologous CD133+ cells or placebo will be performed.
Study NCT01660581 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients in the placebo group receive 0.9% NaCl solution with 0.5% solution of the patient's own serum.
Study NCT00883363 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Precondition
Description: Precondition on a arm in four intervals at start of surgery for ruptured aortic aneurysm
Study NCT02084485 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PH-797804
Description: 30 MG Single dose
Study NCT00688558 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JTT-705 600 mg and simvastatin 40 mg
Description: * JTT-705 300 mg tablets, 600 mg dose, 2 tablets, oral, once daily, immediately following breakfast and/or assessment~* Simvastatin 40 mg tablets, 40 mg dose, one tablet, oral, once daily, immediately following breakfast and/or assessments
Study NCT02084485 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching placebo
Study NCT01801566 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Single implant-retained mandibular overdenture
Description: 60 patients treated with single implant retained complete mandibular denture (overdenture) opposed to a conventional maxillary denture, allocated into 2 experimental groups according to the implant loading protocol (conventional and immediate), evaluated at baseline and after 1, 3, 6 and 12 months after treatment.
Study NCT01801566 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single implant-retained mandibular overdenture
Description: 60 patients treated with single implant retained complete mandibular denture (overdenture) opposed to a conventional maxillary denture, allocated into 2 experimental groups according to the implant loading protocol (conventional and immediate), evaluated at baseline and after 1, 3, 6 and 12 months after treatment.
Study NCT03004365 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: C16G2 Varnish
Description: Antimicrobial Peptide
Study NCT00688558 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo and simvastatin 40 mg
Description: * Placebo tablets, 2 tablets, oral, once daily, immediately following breakfast and/or assessments~* Simvastatin 40 mg tablets, one tablet, oral, once daily, immediately following breakfast and/or assessments
Study NCT01335451 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5213
Description: Four increasing doses for young and two increasing doses for elderly subjects. Subject will receive single dose of AZD5213 oral solution (Day 1) and then start the once daily repeated doses from Day 3 to 12 for 10 days
Study NCT03004365 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Varnish
Description: Placebo
Study NCT02848963 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine-propofol mixture
Description: Ratio of Ketamine-propofol mixture will be compare for every groups.
Study NCT01180465 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LIPO-102
Description: LIPO-102 High dose
Study NCT01180465 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LIPO-102 Low
Description: LIPO-102 Low dose
Study NCT01180465 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LIPO-102, Placebo
Description: Placebo
Study NCT04486534 — intervention group
Intervention type: OTHER
Intervention: Musculoskeletal ultrasound
Description: Subjects' talar cartilage, tibialis anterior and gastrocnemius muscle thickness measurements will be performed using musculoskeletal ultrasound.
Study NCT00688584 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pamphlet-based personalized alcohol feedback (PAF)
Description: participants in this condition will be mailed their respective pamphlets
Study NCT00688584 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: control pamphlet condition
Description: The goal is to test if it is the specific content of the pamphlet that leads to the change or just the receipt of any pamphlet.
Study NCT01842802 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Diode Laser
Description: Diode Laser for treatment of subcutaneous fat
Study NCT01842802 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: YAG laser
Description: YAG laser for treatment of subcutaneous fat
Study NCT03380897 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intervention for outpatient group was to go home
Description: Intervention for outpatient group was to go home and assess the the pain
Study NCT03380897 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Intervention for inpatient group was to stay at ward
Description: Intervention for inpatient group was to stay at ward and assess the pain
Study NCT02093507 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: parents manipulation
Description: parents perform manipulation the child foot to correct the deformity
Study NCT00667888 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Fractionated Intensity Modulated Radiotherapy
Description: A total dose of 75.6 Gy will be delivered in 42 fractions to the planning target volume (PTV).
Study NCT00667888 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated Intensity Modulated Radiotherapy
Description: A total dose of 72 Gy will be delivered in 30 fractions to the PTV.
Study NCT01335451 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo solution, single dose (Day 1) and repeated dose from Day 3 to 12 for 10 days
Study NCT01869127 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Shoes
Description: A unisex canvas slip-on with a sturdy sole.
Study NCT02684773 — intervention group
Intervention type: PROCEDURE
Intervention: Conventional Hemodialysis
Description: The intervention involves 3 hemodialysis sessions/week that consists of 4 hours/session
Study NCT02684773 — intervention group
Intervention type: PROCEDURE
Intervention: In-centre Nocturnal Hemodialysis
Description: The intervention involves 3 hemodialysis sessions/week administered overnight (8 hours/session) in-hospital
Study NCT01808859 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tourniquet
Description: hyperbaric bupivacaine 12.5-15 mg Celecoxib 400 mg and paracetamol 1 g will be given preoperatively. Postoperatively celecoxib 200 mg x 2 and paracetamol 1 g/6 h is given is given for 2 weeks.
Study NCT01945021 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crizotinib
Study NCT03603249 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trimetazidine
Description: Trimetazidine is a clinically effective antianginal agent that has no negative inotropic or vasodilator properties (6). It is presently clinically used throughout Europe and in >80 countries worldwide. It is a cytoprotective drug that normalizes metabolic disturbances in low-flow ischemia via several-not yet fully understood-mechanisms of action (7). The best-known mechanism of action is its capacity to inhibit β-oxidation of free fatty acid (FFA) (7).
Study NCT02319330 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nurse-delivered mobile phone counseling intervention
Description: Multi-dimensional, patient-centered counseling approach used to build patient-provider rapport, establish sources of support, and enable and empower problem solving to address inter-related, multi-tiered barriers to care.
Study NCT02319330 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment as Usual
Description: Routine HIV clinic-based counseling
Study NCT02319330 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Description: Routine HIV clinic-based counseling
Study NCT03636581 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle counseling
Description: This group will receive online education modules to educate them on exercise prescription, nutrition and behavioral changes.
Study NCT01467544 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tai Chi class
Description: The 8-week tai chi group intervention will be lead by Project PI. A focused short form of tai chi involving 12 movements will be used in this project. Each of 8 weekly 60-minute sessions will begin with a 10-minute guided meditation session. Movements learned the previous week will be reviewed prior to introducing new movements. Training DVDs will be produced and provided to participants for weekly and ongoing practice of the techniques.
Study NCT03096340 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IT-141
Description: Escalating doses administered in mg/m2, IV (in the vein) on days 1 and 15 of each 28 day cycle until progression or unacceptable toxicity develops.
Study NCT00634439 — intervention group
Intervention type: DRUG
Intervention: atomoxetine
Study NCT00634439 — intervention group
Intervention type: DRUG
Intervention: Stimulants
Description: Methylphenidate, amphetamines (including Adderall and mixed salts)
Study NCT03988920 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenapanor
Description: NHE3 Inhibitor
Study NCT03988920 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevelamer Carbonate
Description: Phosphate binder
Study NCT02539147 — intervention group
Intervention type: BIOLOGICAL
Intervention: blood samples
Description: Isolation and stimulation of monocytes, preparation of cell lysates, measurement of cytokine production, Western blot
Study NCT00634439 — intervention group
Intervention type: OTHER
Intervention: No intervention (general population)
Study NCT02251626 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: coenzyme Q10
Description: It is a randomized and double blind study so patients or his/her doctor will not know which group s/he is in.
Study NCT02251626 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: It is a randomized and double blind study so patients or his/her doctor will not know which group s/he is in.
Study NCT02039232 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pedicle screw system
Study NCT00804531 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Visipaque - Hydrocortancyl
Description: Visipaque 320 mg I/ml - 1 ml intra-discal route Hydrocortancyl 25 mg/ml - 1 ml intra-discal route
Study NCT01191723 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: MAP0004
Description: 3.0mg orally inhaled MAP0004 administered in Treatment B as per protocol
Study NCT01191723 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Inhaler Placebo
Description: Placebo for Inhaler administered in Treatments A and C
Study NCT00804531 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator
Description: Visipaque - 320 mg I/ml - 1 ml in intra-discal route
Study NCT01587391 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to BI 163538 XX
Description: 1 single dose per subject as oral solution
Study NCT01191723 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Moxifloxacin
Description: 400mg encapsulated tablet administered in Treatment A as per protocol
Study NCT01191723 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo Capsule
Description: Placebo for Moxifloxacin administered in Treatment B and Treatment C
Study NCT01587391 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 163538 XX
Description: 1 single dose per subject as oral solution
Study NCT02047331 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: periarticular injection
Description: patients were performed bupivacaine solution to the periarticular soft tissues during surgery by the surgeon.
Study NCT02047331 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: fascia iliaca block
Description: patients were performed fascia iliaca block with bupivacaine solution before surgery.
Study NCT00936741 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mifepristone
Description: Mifepristone 300 mg to 1200 mg once daily